ArticleBone reports2021
Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients.
Article in Bone reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Bone health across the lifespan in African populations affected by HIV.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2026Article
- Linking the relationship between drug-induced osteoporosis and the gut microbiota.Frontiers in endocrinology · 2026Review
- Breaking Down Bone Disease in People Living with HIV: Pathophysiology, Diagnosis, and Treatment.Advances in experimental medicine and biology · 2025Review
- Effect of Oral Bisphosphonates on Vertebral Fractures in Males Living with HIV: A Seven Year Study.Journal of clinical medicine · 2024Article
- Bone Disease in HIV: Need for Early Diagnosis and Prevention.Life (Basel, Switzerland) · 2024Review
- Article
- Adherence of denosumab treatment for low bone mineral density in Japanese people living with HIV: a retrospective observational study.Journal of pharmaceutical health care and sciences · 2023Article
- Bone Health in People Living with HIV/AIDS: An Update of Where We Are and Potential Future Strategies.Microorganisms · 2023Review
- The efficacy of denosumab in Korean male patients with osteoporosis.The Korean journal of internal medicine · 2022Article
- Osteoporosis and HIV Infection.Calcified tissue international · 2022Review
- Metabolic Complications of Chronic HIV Infection: A Narrative Review.Pathogens (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe aimed to compare annual changes in the bone mineral density (BMD) at the lumbar spine (LS) and the femoral neck (FN) in males with HIV-associated osteoporosis treated with either zoledronate (ZOL) or denosumab (Dmab).
methodsIn this open label, 12-month, prospective, multicenter, cohort study, 23 male people living with HIV (PLWH) under
resultsLS-BMD increased within both treatment groups at 12 months (ZOL 5.43% ± 3.60%,
conclusionsIn male PLWH under ART requiring osteoporosis treatment both ZOL and Dmab are efficient and well tolerated therapeutic options achieving BMD increases at least for the first year of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.